Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Jumped Higher Today

By Brian Orelli, PhD - May 31, 2018 at 3:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are looking forward to the biotech's presentation at ASCO.


Shares of ImmunoGen (IMGN -1.32%) are up 10.4% at 3:10 p.m. EDT on no apparent news. Most likely, shares of the highly volatile biotech are up as investors jump in ahead of the American Society of Clinical Oncology (ASCO) meeting set to start tomorrow.

So what

In an abstract for ASCO that was released earlier this month, ImmunoGen disclosed data from the phase 1b/2 Forward II trial testing its lead drug, mirvetuximab soravtansine, in combination with a variety of other cancer medications.

In 23 ovarian cancer patients with medium or high expression of FRalpha, which mirvetuximab soravtansine targets, treatment with mirvetuximab soravtansine plus Roche's Avastin produced an overall response rate (ORR) of 48% with a median duration of response of 10.6 months. That's not bad considering these patients could have failed up to three previous treatments.

Woman in a head scarf holding hands with another woman

Image source: Getty Images.

A separate set of 10 patients received mirvetuximab soravtansine plus the chemotherapy carboplatin, which produced an ORR of 80% with a median duration of response that hadn't been reached at the cutoff. These patients haven't progressed as far as the Avastin combination group, so it's certainly not an apples-to-apples comparison. In fact, ImmunoGen thought both sets of data were promising enough to justify testing a triplet combination of mirvetuximab soravtansine plus carboplatin and Avastin, which began recently.

Now what

ASCO abstracts have to be turned in months before the meeting, so presentation of the data -- especially the Avastin data on Monday -- could have updated results further solidifying the combination as a potential treatment for ovarian cancer.

The combination data is important to ImmunoGen's long-term future, but investors shouldn't forget about the Forward I trial, testing mirvetuximab soravtansine as a monotherapy since results from that trial, which are due out in the first half of next year, are the quickest way for ImmunoGen to get the drug on the market.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends ImmunoGen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$5.24 (-1.32%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.